The Changing Face of Drug Discovery: New Approaches, New Skills and New Technologies
Sponsored by: Thomson Reuters
Date: 19 July
Time: 3PM London / 10AM New York
The new approaches, new skills and new technologies needed in todayâ€™s drug discovery environment
Increased pipeline attrition coupled to increased R&D spending means that drug discovery within Pharmaceutical companies is becoming ever more expensive and increasingly unproductive. The current late-stage failure rate is unsustainable: Many drugs that have passed stringent early-stage safety tests fail from a lack of efficacy in Phase II/III. In light of this, Pharmaceutical companies are looking to target novel R&D strategies to maximize the value of R&D assets.
While there have been many constants in drug discovery over the last ten years, there have been significant changes too. Translational Research and recent Quantitative Systems Pharmacology approaches have gained in popularity by offering potential solutions to the challenges faced.
In this webinar we explore potential strategies that can be used by Pharmaceutical companies to enhance their pipeline value and increase success rates. We discuss drug discovery attrition and is it influenced as much by how we conduct pre-clinical drug discovery as by the clinical phase. What are the low hanging fruit targets and, if current pre-clinical drug discovery is flawed, how do we improve the balance of approaches?
Join two of the most influential opinion leaders in the industry today, to discuss the key challenges and how new approaches, new skills and new technologies have the potential to overcome today’s obstacles and have your chance to put questions to them.
Dr. Christopher Lipinski,
Scientific Advisor to Melior Discovery , Exton PA.
Dr. Christopher Lipinski, is one of the key figures in the Industry, having spent 32 years at Pfizer rising to Senior Research Fellow (Pfizer's highest scientific position) before retiring in 2002. Over the course of his distinguished career he has authored over 265 publications and invited presentations and has 18 issued US patents. Since its publication in 1997, The Lipinski rule of five has been a critical filter for drug development programs. He has received numerous awards and citations notable ones including Member of the ACS â€œMedicinal Chemistry Hall of Fameâ€ SBS Achievement Award winner, the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances and winner of the Division of Medicinal Chemistry Award of the ACS Division of Medicinal Chemistry. He is currently Scientific Advisor to Melior Discovery a drug repurposing startup in Exton PA,
Professor Andrew L. Hopkins DPhil FRSC FSB,
Prof. of Medicinal Informatics & SULSA Research Prof. of Translational Biology. University of Dundee
Professor Hopkins is specializes in the fields of chemoinformatics, chemogenomics and drug discovery with a focus on developing novel informatics and experimental methods to enable new, more effective, ways of conducting drug discovery. He spent ten years in the pharmaceutical industry prior to moving to academia and is well known globally having authored some of the highest cited papers in the field of Pharmacology published in the past decade. In recent years Andrew has received a number of prestigious awards including: Fellow of the Society of Biology (2011) The 3rd Capps Green Zomaya Award in Medicinal or Computational Chemistry (2008) and Corwin Hansch Award (2007).
Dr Nicola Marlin,
Product Manager at Thomson Reuters
Nicola Marlin has been working within drug discovery and development for over ten years, and has held positions in both Pharma and the Biotech industry, working within the Europe and the Middle East. She has been with Thomson Reuters Scientific for 2.5 years, working in Product Management and acting as an ambassador for our Chemistry information. She has a Ph.D. in Chemistry from Imperial College London and is a Chartered Chemist (Member of the Royal Society of Chemistry).
Key Learning Objectives
- Is drug discovery attrition influenced as much by how we conduct pre-clinical drug discovery as by the clinical phase
- What novel strategies can maximise revenue, reduce cost and mitigate risk in drug R & D
- How do we balance the emerging technologies and techniques to reduce failure rates
- What are the low hanging fruit targets
- CEO/President/Chairman/Executive Director
- CSO/ Chief Scientist
- Head of R&D
- VP R&D
- Scientific Director
- Director R&D
- Director of Chemistry
- Head of Chemistry
- Head of Medicinal Chemistry
- Head of Drug Discovery Head of Discovery Technologies
- Head of Translational Research
- Group Leader Drug Discovery
- Group Leader Medicinal chemistry/ Pharmacology Group Leader
- Senior Scientist
- Principal Scientist
- Medicinal Chemist